as 10-21-2025 3:54pm EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Founded: | 2004 | Country: | United States |
Employees: | N/A | City: | WARREN |
Market Cap: | 809.3M | IPO Year: | 2018 |
Target Price: | $10.71 | AVG Volume (30 days): | 3.6M |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.69 | EPS Growth: | N/A |
52 Week Low/High: | $2.12 - $7.55 | Next Earning Date: | 10-31-2025 |
Revenue: | $44,132,000 | Revenue Growth: | -24.38% |
Revenue Growth (this year): | -20.35% | Revenue Growth (next year): | 51.50% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Boyd Peter E. | AQST | See Remarks | Oct 15 '25 | Sell | $7.00 | 10,000 | $70,000.00 | 268,323 | |
Kraus Carl N | AQST | Chief Medical Officer | Oct 15 '25 | Sell | $7.00 | 20,272 | $141,904.00 | 282,475 | |
Jung Cassie | AQST | Chief Operating Officer | Oct 15 '25 | Sell | $7.01 | 67,575 | $473,700.75 | 240,771 | |
Barber Daniel | AQST | President and CEO | Sep 26 '25 | Sell | $6.03 | 91,343 | $551,191.06 | 923,430 | |
Boyd Peter E. | AQST | See Remarks | Sep 26 '25 | Sell | $6.30 | 10,000 | $63,000.00 | 268,323 | |
Barber Daniel | AQST | President and CEO | Sep 19 '25 | Sell | $6.00 | 400 | $2,400.00 | 923,430 | |
Boyd Peter E. | AQST | See Remarks | Sep 5 '25 | Sell | $5.30 | 15,000 | $79,500.00 | 268,323 | |
Jung Cassie | AQST | Chief Operating Officer | Sep 4 '25 | Sell | $5.00 | 62,180 | $310,900.00 | 240,771 |
AQST Breaking Stock News: Dive into AQST Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Simply Wall St.
12 days ago
MT Newswires
13 days ago
MT Newswires
13 days ago
MT Newswires
13 days ago
MT Newswires
13 days ago
MT Newswires
13 days ago
GlobeNewswire
14 days ago
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.